VGN-R08b GBA1 gene therapy (Vitalgen)

The research record

This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".

Who

Shanghai Vitalgen BioPharma. The listed site is Xiangya Hospital, Central South University (Changsha, China). Registered as NCT07414290.

What happened

Mutations in GBA1 are the most common genetic risk factor for Parkinson's (landmark 16). They lower the activity of the enzyme GCase and may let alpha-synuclein build up (landmark 35). VGN-R08b is a gene therapy that delivers a working copy of the gene. The registry's outcome list refers to antibodies against "AAV9 and GCase", so the vector is an AAV9. It is injected into the cerebral ventricles (the fluid-filled chambers in the brain), not into the tissue.

Design: open-label, non-randomised, Phase 1/2, about 17 people aged 30 to 70 with a pathogenic GBA1 mutation, low blood GCase activity, and Hoehn-Yahr stage 3 to 4 when off medication. Three dose groups of three people (4.2×10^13, 8.4×10^13 and 1.68×10^14 vector genomes) are dosed one person first, then the rest after 4 weeks of safety checks; further patients follow in a second part. The primary outcome is adverse events up to week 52. Secondary outcomes include GCase activity, a fat marker (glucosylceramide) in blood and spinal fluid, motor scores, and immune responses, for up to 5 years.

The registry estimated a start on 25 May 2026 (status last verified February 2026, last updated 1 May 2026, still "not yet recruiting" when checked on 19 Oct 2026) and primary completion on 1 Sep 2027, with completion in September 2031. Participants must also have a MDS-UPDRS part III score of at least 33 off medication and be on optimised levodopa with at least 2.5 hours a day of "off" time. A drug database search summary also reported a US IND approval on 28 Sep 2025; this was not confirmed from a primary source.

Why it moved us toward a cure

It aims at the cause in a genetic subgroup, not the symptoms: restoring the enzyme that GBA1 carriers lack. It parallels Lilly's PR001 (landmark 109) and uses a different delivery route.

Outcome

Open. No participant has been reported dosed in the registry or in a search for company news (22 Oct 2026), and the estimated start date has passed without an update. Safety and enzyme levels will come before any test of slowing.

Sources

• ClinicalTrials.gov NCT07414290 (API re-read 22 Oct 2026: still "not yet recruiting", last update 1 May 2026, one site)
• Sponsor listing, via search: Reagan-Udall Expanded Access Navigator
• Not yet verified: whether dosing has started; the US IND claim; the vector's exact capsid and promoter; any Vitalgen release. The sponsor's VGN-R08b trials in Gaucher disease (NCT06272149, type 2, recruiting; NCT07603050, listed as not yet recruiting) were not read.